The Medicines Company has received FDA’ pediatric exclusivity for Angiomax (bivalirudin), based on studies submitted in response to a written request by FDA, for pediatric patients aged under 16.
Human Genome Sciences has announced that Novartis has completed enrollment and initial dosing in a Phase 2b clinical trial, to evaluate the safety and efficacy of Albuferon (albinterferon
China Medical Technologies has posted unaudited preliminary financial results for the fourth fiscal quarter, 2008 and the full year of the fiscal 2008. The company reports an
SOCMA has joined an international consortium, which works to enhance security and assure the quality and authenticity of products moving through the drug supply chain. SOCMA is
Innocoll has declared positive provisional findings from its three phase-II clinical trials, to investigate collarx gentamicin topical for the treatment and prevention of infection in diabetic foot ulcers.
FDA has removed the clinical hold from Aastrom’ US phase-II Impact-Dcm clinical trial. Patient enrollment would resume at all five initiated clinical sites. The Impact-Dcm trial is evaluating
Vical is proceeding with the development of the RapidResponse platform under the third year of grant funding, awarded by the National Institute of Allergy and Infectious Diseases (NIAID).
Oculus Innovative (Oculus) has reported preliminary results from its US 40-patient feasibility study, for the treatment of acne with Microcyn hydrogel formulation Cheryl Bongiovanni, Director, Lakes Aesthetics Center,
BioLine has announced the initiation of phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of
KV Pharmaceutical has signed an agreement with Gedeon Richter, USA for licensing rights to some of KV’ technologies and products in Women’s Health. Under this agreement, Gedeon Richter
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.